A5038470546- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Spondyloarthritis Studies and Treatments
- Autoimmune Bullous Skin Diseases
- Ocular Diseases and Behçet’s Syndrome
- Cutaneous lymphoproliferative disorders research
- Rheumatoid Arthritis Research and Therapies
- Urticaria and Related Conditions
- Hair Growth and Disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Skin Protection and Aging
- Body Image and Dysmorphia Studies
- Wound Healing and Treatments
- Dupuytren's Contracture and Treatments
- Empathy and Medical Education
- Tumors and Oncological Cases
- Acne and Rosacea Treatments and Effects
- Complementary and Alternative Medicine Studies
- melanin and skin pigmentation
- Atherosclerosis and Cardiovascular Diseases
- Antifungal resistance and susceptibility
- Clinical practice guidelines implementation
- Mast cells and histamine
- Psoriasis: Treatment and Pathogenesis
- Hypertrophic osteoarthropathy and related conditions
British Association of Dermatologists
2020-2024
Plain language summary available online The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for management cutaneous squamous cell carcinoma (cSCC). document aims presented as a detailed review with highlighted practical use in primary, secondary and tertiary care, clinic appropriate skin cancer multidisciplinary team (MDT) meetings (see section 3.0). These may be either local MDTs (LSMDTs) or specialist (SSMDTs), depending on clinicopathological...
Linked Comment: M.D. Moncrieff and J.P. Nobes. Br J Dermatol 2021; 185:877. Plain language summary available online
Abstract Linked Comment: K. Ezzedine and A.G. Pandya. Br J Dermatol 2022; 186:3–4. Plain language summary available online
Plain language summary available online The guideline is presented as a detailed review with highlighted recommendations for practical use in primary, secondary and tertiary care, addition to an updated patient information leaflet (PIL; on the BAD Skin Health Information website, https://www.skinhealthinfo.org.uk/a-z-conditions-treatments). Other than providing background information, does not cover angio-oedema without weals [other idiopathic, which now classified part of chronic...
Linked Comment: J.S.S. Ho and Y. Asai. Br J Dermatol 2021; 185:689–690. Plain language summary available online
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for management squamous cell carcinoma in situ (SCC situ). document aims to: offer an appraisal all relevant literature up 13th August 2021, focusing on any key developments; address important, practical clinical questions relating primary objective; and if appropriate research recommendations.
Abstract Linked Comment: P. Wolf. Br J Dermatol 2022; 187:285–286.
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for management delusional infestation (DI) in adults. Linked Comment: I. Coulson. Br J Dermatol 2022; 187:457.
The guideline is presented as a detailed review with highlighted recommendations for practical use in primary care and secondary (see section 3.0), addition to an updated patient information leaflet (available on the BAD Skin Health Information website, https://www.skinhealthinfo.org.uk/a-z-conditions-treatments/). does not cover Jessner lymphocytic infiltrate or nonspecific cutaneous manifestations of lupus such vasculitis Raynaud phenomenon. This set guidelines has been developed using...
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for management Behçets. document aims offer an appraisal all relevant literature up 25 August 2023 focusing on any key developments; address important, practical clinical questions relating primary objective; and appropriate research recommendations.
The overall objective of the current iteration this living guideline is to provide up-to-date, evidence-based recommendations for management alopecia areata (AA) in adults (≥18 years age), children (0-12 age) and young people (13-17 age).